on October 17, 2005
Published online before print October 17, 2005, doi: 10.1161/01.HYP.0000187899.34379.b0
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 12, 2005
From the Renal Division (C.L., S.A.K.), Department of Medicine, and the Department of Obstetrics and Gynecology (K.-H.L., S.A.K.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass. * To whom correspondence should be addressed. E-mail: sananth{at}bidmc.harvard.edu.
Abstract--Preeclampsia is a major cause of maternal, fetal, and neonatal mortality worldwide. Although the etiology of preeclampsia is still unclear, recent studies suggest that its major phenotypes, high blood pressure and proteinuria, are due in part to excess circulating soluble fms-like tyrosine kinase-1 concentrations. Soluble fms-like tyrosine kinase-1 is an endogenous antiangiogenic protein that is made by the placenta and acts by neutralizing the proangiogenic proteins vascular endothelial growth factor and placental growth factor. High serum soluble fms-like tyrosine kinase-1 and low serum free placental growth factor and free vascular endothelial growth factor have been observed in preeclampsia. Abnormalities in these circulating angiogenic proteins are not only present during clinical preeclampsia but also antedate clinical symptoms by several weeks. Therefore, this raises the possibility of measuring circulating angiogenic proteins in the blood and the urine as a diagnostic and screening tool for preeclampsia. The availability of a test to predict preeclampsia would be a powerful tool in preventing preeclampsia-induced mortality, especially in developing nations, where high-risk specialists are limited. This review will summarize our current understanding of the role of circulating angiogenic proteins in the pathogenesis and clinical diagnosis/prediction of preeclampsia.
Revised on July 19, 2005
Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia
Chun Lam;
Key words: angiogenesis • vasculature • proteinuria • hypertension, pregnancy • preeclampsia
This article has been cited by other articles:
 |
|
 |
|
  T. E. Walshe, V. S. Dole, A. S.R. Maharaj, I. S. Patten, D. D. Wagner, and P. A. D'Amore Inhibition of VEGF or TGF-{beta} Signaling Activates Endothelium and Increases Leukocyte Rolling Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wang, S. Rana, and S. A. Karumanchi Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis Physiology, June 1, 2009; 24(3): 147 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Sandrim, A. C. T. Palei, R. C. Cavalli, F. M. Araujo, E. S. Ramos, G. Duarte, and J. E. Tanus-Santos Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension Mol. Hum. Reprod., February 1, 2009; 15(2): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Gilbert, S. A.B. Gilbert, M. Arany, and J. P. Granger Hypertension Produced by Placental Ischemia in Pregnant Rats Is Associated With Increased Soluble Endoglin Expression Hypertension, February 1, 2009; 53(2): 399 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Iacob, J. Cai, M. Tsonis, A. Babwah, C. Chakraborty, R. N. Bhattacharjee, and P. K. Lala Decorin-Mediated Inhibition of Proliferation and Migration of the Human Trophoblast via Different Tyrosine Kinase Receptors Endocrinology, December 1, 2008; 149(12): 6187 - 6197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. LaMarca, G. Wallukat, M. Llinas, F. Herse, R. Dechend, and J. P. Granger Autoantibodies to the Angiotensin Type I Receptor in Response to Placental Ischemia and Tumor Necrosis Factor {alpha} in Pregnant Rats Hypertension, December 1, 2008; 52(6): 1168 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Plaisier, E. Streefland, P. Koolwijk, V.W.M. van Hinsbergh, F.M. Helmerhorst, and J.J.H.M. Erwich Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction Reproductive Sciences, September 1, 2008; 15(7): 720 - 726. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W.G. Redman The Endoplasmic Reticulum Stress of Placental Impoverishment Am. J. Pathol., August 1, 2008; 173(2): 311 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Salmon and P. de Groot Pathogenic role of antiphospholipid antibodies Lupus, May 1, 2008; 17(5): 405 - 411. [Abstract] [PDF]
|
|
|
|
|
|
B. D. LaMarca, J. Gilbert, and J. P. Granger Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia Hypertension, April 1, 2008; 51(4): 982 - 988. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Thomas, J. I. Andrews, and K. Z. Liu Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta FASEB J, December 1, 2007; 21(14): 3885 - 3895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gilbert, S. A. Babcock, and J. P. Granger Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression Hypertension, December 1, 2007; 50(6): 1142 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Berkane, G. Lefevre, and A. Hertig Angiogenic factors in preeclampsia: so complex, so simple? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2753 - 2756. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Troisi, N. Potischman, and R. N. Hoover Exploring the Underlying Hormonal Mechanisms of Prenatal Risk Factors for Breast Cancer: A Review and Commentary Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1700 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Stepan, T. Kramer, and R. Faber Maternal Plasma Concentrations of Soluble Endoglin in Pregnancies with Intrauterine Growth Restriction J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2831 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. D'Amore Vascular Endothelial Cell Growth Factor-A: Not Just for Endothelial Cells Anymore Am. J. Pathol., July 1, 2007; 171(1): 14 - 18. [Full Text] [PDF]
|
|
|
|
|
|
H. Stepan, A. Unversucht, N. Wessel, and R. Faber Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion Hypertension, April 1, 2007; 49(4): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hubel, G. Wallukat, M. Wolf, F. Herse, A. Rajakumar, J. M. Roberts, N. Markovic, R. Thadhani, F. C. Luft, and R. Dechend Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia Hypertension, March 1, 2007; 49(3): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cohen, K.-H. Lim, Y. Lee, S. Rana, S. A. Karumanchi, and F. Brown Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic markers in preeclampsia and preexisting diabetes Diabetes Care, February 1, 2007; 30(2): 375 - 377. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction J. Exp. Med., September 4, 2006; 203(9): 2165 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gellhaus, M. Schmidt, C. Dunk, S. J. Lye, R. Kimmig, and E. Winterhager Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associatedwith pre-eclampsia Mol. Hum. Reprod., June 1, 2006; 12(6): 389 - 399. [Abstract] [Full Text] [PDF]
|
|